LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Files An 8-K Other Events
ITEM 8.01 OTHER EVENTS.
issued a press release announcing that results of the ATHOS-3
(Angiotensin II for the Treatment of High-Output Shock) Phase 3
study of LJPC-501 (angiotensin II) have been published online by
The New England Journal of Medicine (NEJM). A copy of the press
release is attached as Exhibit 99.1 to this Current Report on
Form 8-K.
report on Form 8-K:
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Press Release dated May 21, 2017
|
About LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC)
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. Its product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. The Company is developing LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). The Company is developing LJPC-401 for the treatment of iron overload, which occurs as a result of diseases, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. It is developing LJPC-30Sa and LJPC-30Sb not only for the treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) Recent Trading Information
LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ:LJPC) closed its last trading session 00.00 at 34.00 with 1,110,479 shares trading hands.